Table of Contents
- What is Enfortumab Vedotin?
- How Does It Work?
- What Conditions Does Enfortumab Vedotin Treat?
- How is Enfortumab Vedotin Administered?
- Clinical Trials and Research
- Potential Side Effects
- Patient Monitoring and Follow-up
What is Enfortumab Vedotin?
Enfortumab Vedotin is a type of cancer medication known as an antibody-drug conjugate (ADC). It’s also referred to by its brand name PADCEV and research code names such as ASG-22CE or ASG-22ME[1][2]. This innovative treatment combines a targeted antibody with a powerful anti-cancer drug. The antibody part of the medication, called enfortumab, is designed to seek out specific cancer cells. Once it finds these cells, it delivers the attached drug, vedotin, directly to them[3].
How Does It Work?
Enfortumab Vedotin works in a unique way to fight cancer:
- Targeting: The enfortumab antibody attaches to a protein called Nectin-4, which is found on the surface of certain cancer cells[3].
- Delivery: Once attached, the medication is absorbed by the cancer cell.
- Cell Death: Inside the cell, the vedotin part is released. This drug disrupts the cell’s internal structure (specifically, its microtubules), leading to cell death[4].
This targeted approach helps to attack cancer cells while potentially reducing damage to healthy cells, which may lead to fewer side effects compared to traditional chemotherapy.
What Conditions Does Enfortumab Vedotin Treat?
Enfortumab Vedotin is primarily used to treat several types of cancer, including:
- Urothelial Cancer: This is the main type of bladder cancer. It can also occur in other parts of the urinary system, such as the renal pelvis (part of the kidney), ureter (the tube connecting the kidney to the bladder), or urethra (the tube that carries urine out of the body)[1].
- Advanced or Metastatic Urothelial Cancer: This refers to cancer that has spread beyond its original location to other parts of the body[5].
- Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis: A type of skin cancer that affects the penis and has either spread locally or to other parts of the body[3].
Research is also ongoing to explore the effectiveness of Enfortumab Vedotin in treating other types of cancer, including:
- Non-muscle Invasive Bladder Cancer (NMIBC): A type of bladder cancer that has not yet spread into the muscle layer of the bladder wall[6].
- Metastatic Colorectal Cancer: Cancer of the colon or rectum that has spread to other parts of the body[7].
- Hepatocellular Carcinoma: The most common type of liver cancer[7].
- Metastatic Castration-resistant Prostate Cancer: An advanced form of prostate cancer that continues to progress despite treatments that lower testosterone levels[8].
- Pancreatic Ductal Adenocarcinoma: The most common type of pancreatic cancer[4].
How is Enfortumab Vedotin Administered?
Enfortumab Vedotin is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The usual schedule is:
- Once a week for 3 weeks (on days 1, 8, and 15)
- Followed by a week off (making a complete 28-day cycle)
The dose is usually calculated based on your body weight, with a common dose being 1.25 mg per kilogram of body weight[5]. Your healthcare team will determine the right dose and schedule for you based on your specific situation.
Treatment typically continues until the cancer progresses or side effects become too severe. In some cases, treatment may last for a set period, such as up to 12 months[8].
Clinical Trials and Research
Enfortumab Vedotin has been and continues to be studied in various clinical trials. These studies help researchers understand how well the drug works for different types of cancer, what the optimal dosing might be, and what side effects patients may experience. Some key areas of research include:
- Combination Therapies: Researchers are studying how Enfortumab Vedotin works when combined with other cancer treatments[8].
- New Cancer Types: While primarily used for urothelial cancers, studies are exploring its effectiveness in other cancer types like colorectal, liver, prostate, and pancreatic cancers[7][4].
- Different Stages of Cancer: Some trials are looking at using Enfortumab Vedotin for earlier stages of bladder cancer[6].
- New Methods of Administration: While typically given intravenously, some studies are exploring giving the drug directly into the bladder for certain types of bladder cancer[6].
Potential Side Effects
Like all medications, Enfortumab Vedotin can cause side effects. It’s important to discuss these with your healthcare team. Some potential side effects include:
- Fatigue: Feeling very tired or weak
- Nausea and vomiting
- Decreased appetite
- Diarrhea
- Rash or skin reactions
- Neuropathy: Numbness, tingling, or pain in hands or feet
- Changes in blood tests: Such as decreased red or white blood cell counts
More serious side effects can occur but are less common. Your healthcare team will monitor you closely for any side effects and can help manage them if they occur[1][9].
Patient Monitoring and Follow-up
When receiving Enfortumab Vedotin, you will be closely monitored by your healthcare team. This typically includes:
- Regular check-ups: To assess your overall health and how you’re tolerating the treatment.
- Blood tests: To check your blood cell counts and organ function.
- Imaging scans: Such as CT or MRI scans to evaluate how the cancer is responding to treatment.
- Side effect management: Your team will help you manage any side effects that occur.
After completing treatment, you’ll likely have follow-up appointments to monitor for any signs of cancer recurrence and to manage any long-term effects of treatment. The frequency of these appointments can vary but might start at every few months and become less frequent over time[3][9].
